Investigational drug · Phase 3
Cobolimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "Cobolimab"
First trial start
2020
Dec 8, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cobolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Hodgkin Lymphoma
- High and Low Grade Glioma
- Glioblastoma Multiforme (GBM)
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Ependymoma
- Osteosarcoma
- Hepatic Tumors
- Hepatoblastoma
- Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Melanoma · Liver cancer (hepatocellular carcinoma) · Brain tumors (glioma) · Sarcoma · Hodgkin lymphoma · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Cobolimab" as an intervention, largest first.
GlaxoSmithKlineGSK (GSK)
NCT02723955 · 829 participants · Start Jun 23, 2016 · Primary completion Jul 5, 2023
Drug: feladilimab (GSK3359609); GSK3174998 and 9 more · For: Neoplasms
Sites: Duarte, California; Los Angeles, California; Sarasota, Florida · 28 sites in all
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04655976 · 758 participants · Start Dec 8, 2020 · Primary completion Jun 5, 2025
Drug: Cobolimab; Dostarlimab and 1 more · For: Lung Cancer, Non-Small Cell
Sites: Fountain Valley, California; Walnut Creek, California; Norwich, Connecticut · 163 sites in all
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04446351 · 107 participants · Start Jun 25, 2020 · Primary completion Dec 31, 2026
Drug: GSK6097608; Dostarlimab and 2 more · For: Neoplasms
Sites: Los Angeles, California; Boston, Massachusetts; Dallas, Texas · 11 sites in all
- A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06521567 · 83 participants (planned) · Start Mar 6, 2025 · Primary completion Oct 13, 2026
Drug: Cobolimab; Dostarlimab · For: Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma and 9 more
Sites: Los Angeles, California; Iowa City, Iowa; Hackensack, New Jersey · 20 sites in all
- Dostarlimab and Cobolimab in Advanced Cervical CancerActive, not recruiting
Meghan SheaAcademic, hospital or other
NCT06238635 · 66 participants (planned) · Start Mar 11, 2024 · Primary completion Dec 1, 2026
Drug: Dostarlimab; Cobolimab · For: Cervical Cancer; Advanced Cervical Carcinoma; Metastatic Cervical Cancer and 2 more
Sites: Boston, Massachusetts · 2 sites in all
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in MelanomaActive, not recruiting
Diwakar DavarAcademic, hospital or other
NCT04139902 · 58 participants · Start Jun 12, 2020 · Primary completion Sep 29, 2025
Drug: Dostarlimab (TSR-042) (singly); Dostarlimab (TSR-042) and TSR-022 (combination) · For: Melanoma Stage III; Melanoma Stage IV
Sites: Washington D.C., District of Columbia; Boston, Massachusetts; Pittsburgh, Pennsylvania · 5 sites in all
- TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver CancerActive, not recruiting
University of HawaiiAcademic, hospital or other
NCT03680508 · 42 participants · Start Dec 19, 2019 · Primary completion Mar 6, 2026
Drug: TSR-022 and TSR-042 · For: Adult Primary Liver Cancer; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer
Sites: Honolulu, Hawaii; Portland, Oregon
Newest research
PubMed records naming it or its code names, newest first.
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A.
Davar D, Eroglu Z, Pérez CL, et al. · Clin Cancer Res 2025
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
Davar D, Eroglu Z, Milhem M, et al. · Clin Cancer Res 2025
- New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.
Gomes de Morais AL, Cerdá S, de Miguel M · Curr Oncol Rep 2022
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.